Study points to a phosphorylation pathway that may contribute to the
development of lung injury and fibrosis
A study by researchers at the University of California, San Diego School of
Medicine may lead to a way to prevent the progression, or induce the regression,
of lung injury that results from use of the anti-cancer chemotherapy drug
Bleomycin. Pulmonary fibrosis caused by this drug, as well as Idiopathic
Pulmonary Fibrosis (IPF) from unknown causes, affect nearly five million people
worldwide. No therapy is known to improve the health or survival of
Their research shows that the RSK-C/EBPβphosphorylation pathway may
contribute to the development of lung injury and fibrosis, and that blocking
this phosphorylation – a regulatory mechanism in which proteins and receptors
are switched on or off – improved Bleomycin-induced lung fibrosis in mice. The
study appears on-line October 5 in Proceedings of the Library of
Science (PloS ONE).
Read the entire article at:
or go to www.ipftoday.com for more news.